BioSpace News Archive

Turn Therapeutics™, Inc., a Los Angeles-based pharmaceutical and medical device company, has announced FDA clearance of Protego™ Antimicrobial Wound Dressing, an important and disruptive innovation to traditional petroleum saturated gauze dressings.

Rezolute, Inc., announced that senior management will present at the 2019 BIO Investor Forum Conference in San Francisco on Tuesday, October 22, 2019 at 9:00 a.m. PT.

Health Canada is advising Canadians who use vaping products to monitor themselves for symptoms of pulmonary illness and to seek medical attention promptly if they have concerns about their health..

Consumers and pharmacists should check that devices can be removed from their carrier tubes with ease

Theratechnologies Inc. is pleased to announce that results from a recent trial conducted at the Massachusetts General Hospital and the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health on the effects of tesamorelin on Non-alcoholic Fatty Liver Disease in HIV were published in the Lancet HIV.

Unitedcoatings Group announces today that following its acquisition of CoorsTek Medical in July of 2019, the entity will be rebranded as Lincotek Medical.

Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that three abstracts highlighting clinical and nonclinical data for bardoxolone methyl (bardoxolone) will be presented at the American Society of Nephrology Kidney Week 2019 Annual Meeting being held from November 5 – 10, at the Walter E. Washington Convention Center in Washington, D.C.

We are increasingly concerned by the substantial rise of vaping among Canadian youth. As nicotine in any form is highly addictive, non-smokers who vape products containing nicotine are at risk of going on to use tobacco products such as cigarettes.

On Wednesday, Oct. 9, Rep. Lucy McBath (GA-06) hosted a conversation with AARP Georgia members and volunteers in Georgia’s Sixth Congressional District to talk about the rising cost of prescription drugs

Shionogi & Co., Ltd. announced that it has entered into a new license agreement with Hsiri Therapeutics, Inc. regarding a collaborative research and development program to discover and develop additional novel therapeutics for non-tuberculous mycobacterial diseases and tuberculosis.